IMPACT OF IMMUNE-CHECKPOINT INHIBITORS ON LONG-TERM DISEASE COURSE OF AND DEVELOPMENT OF MICROSCOPIC COLITIS

被引：0
|
作者：
Fredrick, Thomas W.
Ramos, Guilherme P.
Braga Neto, Manuel B.
Kane, Sunanda V.
Faubion, William
Loftus, Edward V.
Pardi, Darrell S.
Raffals, Laura H.
机构：
来源：
GASTROENTEROLOGY | 2021年 / 160卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
242
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [31] Exploring the prognostic impact of absolute lymphocyte count in patients treated with immune-checkpoint inhibitors
    M. R. Conroy
    H. O’Sullivan
    D. C. Collins
    R. M. Bambury
    D. Power
    S. Grossman
    S. O’Reilly
    BJC Reports, 2 (1):
  • [32] Outcomes following long-term response to immune checkpoint inhibitors in patients with advanced melanoma
    Handel, Eleanor
    McKeown, Janet
    Wei, Joe
    Kankaria, Roma
    Burnette, Hannah
    Lawless, Aleigha
    Czapla, Juliane
    Albrecht, Lea Jessica
    Mangana, Joanna
    Kessels, Jolien Isabel
    Allayous, Clara
    Boatwright, Christina Ann
    Ottaviano, Margaret
    Czarnecka, Anna Malgorzata
    Rutkowski, Piotr
    Lo, Serigne N.
    Long, Georgina V.
    Menzies, Alexander M.
    Carlino, Matteo S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data
    Bossageon, Maxime
    Swalduz, Aurelie
    Chouaid, Christos
    Bylicki, Olivier
    BIODRUGS, 2022, 36 (02) : 137 - 151
  • [34] First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data
    Maxime Boussageon
    Aurélie Swalduz
    Christos Chouaïd
    Olivier Bylicki
    BioDrugs, 2022, 36 : 137 - 151
  • [35] Immune-checkpoint inhibitor-related microscopic colitis: clinical pictorial series and histopathological mini-review
    Chang, A.
    Bearblock, E.
    Chang, K.
    Chang, F.
    VIRCHOWS ARCHIV, 2024, 485 : S473 - S474
  • [36] Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
    Wang, Zhenghang
    Liu, Chang
    Bai, Yuezong
    Zhao, Xiaochen
    Cui, Longgang
    Peng, Zhi
    Zhang, Xiaotian
    Wang, Xicheng
    Zhao, Zhengyi
    Li, Jian
    Shen, Lin
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [37] Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors
    Wakuda, Kazushige
    Yabe, Michitoshi
    Kodama, Hiroaki
    Nishioka, Naoya
    Miyawaki, Taichi
    Miyawaki, Eriko
    Mamesaya, Nobuaki
    Kobayashi, Haruki
    Omori, Shota
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Shimizu, Tetsuo
    Gon, Yasuhiro
    Takahashi, Toshiaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (12) : 1736 - 1743
  • [38] Correction to: First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data
    Maxime Boussageon
    Aurélie Swalduz
    Christos Chouaïd
    Olivier Bylicki
    BioDrugs, 2023, 37 : 121 - 121
  • [39] Use of Late-Life Expectancy for Assessing the Long-Term Benefit of Immune Checkpoint Inhibitors
    Vivot, Alexandre
    Crequit, Perrine
    Porcher, Raphael
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2019, 111 (05): : 519 - 521
  • [40] Long-term survival outcomes with immune checkpoint inhibitors (ICI) in metastatic uveal melanoma (MUM).
    Lee, Cha Len
    Walsh, Naomi
    Keane, Fergus
    Lynch, Emer
    Reddan, Tadhg
    Craig, Helen
    O'Meara, Aileen
    Smith, Deirdre
    O'Neill, Valerie
    Horgan, Noel
    Kennedy, Susan
    Gullo, Giuseppe
    Crown, John
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345